GlassScriptPhysician profile
Bradley G Somer
NPI 1851320691
$162,981.24
in general payments reported to CMS, 2019-2025
57 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,812 · 2020: $19K · 2021: $7,378 · 2022: $12K · 2023: $33K · 2024: $33K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Consulting Fee: $46K · Travel and Lodging: $12K · Food and Beverage: $4,046 · Long Term Medical Supply Or Device Loan: $1,496 · Education: $84.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,472.50 |
| Consulting Fee | $46,239.74 |
| Travel and Lodging | $12,137.68 |
| Food and Beverage | $4,045.80 |
| Long Term Medical Supply Or Device Loan | $1,495.50 |
| Education | $84.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35,149.22 | 2019-2025 | Lynparza, Truqap, Imfinzi |
| Merck Sharp & Dohme LLC | $31,912.02 | 2019-2025 | Welireg, Keytruda, Keytruda Qlex |
| Amgen INC. | $18,052.03 | 2019-2025 | Vectibix, Vectibix, Blincyto |
| Pfizer INC. | $10,426.15 | 2019-2025 | |
| Seagen INC. | $9,373.88 | 2021-2023 | Padcev |
| Eisai INC. | $7,302.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,976.23 | 2019-2025 | |
| Array Biopharma INC | $5,122.95 | 2022-2023 | Braftovi, Mektovi |
| Exelixis INC. | $3,849.46 | 2019-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $3,684.15 | 2023-2024 | Fruzaqla, Ninlaro |
| Avyxa Pharma, LLC | $3,326.96 | 2025 | |
| Aveo Pharmaceuticals, INC. | $3,033.70 | 2021-2024 | |
| Athenex Pharmaceutical Division, LLC | $2,750.00 | 2020 | |
| Astellas Pharma Global Development | $2,704.00 | 2024 | Vyloy |
| Genzyme Corporation | $2,615.22 | 2021-2023 |
Show all 53 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Somer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.